A5025878578- Chronic Kidney Disease and Diabetes
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Renal Diseases and Glomerulopathies
- Lipoproteins and Cardiovascular Health
- Dialysis and Renal Disease Management
- Peripheral Artery Disease Management
- Diabetes Treatment and Management
- Inflammatory Biomarkers in Disease Prognosis
University of Arkansas for Medical Sciences
2022-2024
No study has compared pharmacologic properties of ticagrelor and clopidogrel in non-dialysis patients with stage 4–5 chronic kidney disease (CKD). We conducted a double-blind RCT to compare effects 48 CKD, the primary outcome ADP-induced platelet aggregation (WBPA) after 2 weeks DAPT. In parallel arm, we plus aspirin on mean changes WBPA markers thromboinflammation among non-CKD controls (n = 26) that CKD ticagrelor-arm. Average age was 53.7 years, 62% women, 54% African American, 42% 5 CKD....
Davis, Otis M BS; Kore, Rajshekhar PhD; Moore, Alexandra Ware, Jerry Mehta, Jawahar L MD, Arthur, John Lynch, Donald R MSCI; Jain, Nishank MPH Author Information
Dear editors, we would like to counter the questions raised by Helvaci et al.1Challenging Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD. O, Yasar E. B. Kidney Int Rep.Google Scholar regarding beneficial effects of SGLT2i absence RAASi and albuminuria when eGFR is >45. these 2 clinical settings remain debatable based on all data available. For first setting, although subgroup analyses EMPA-KIDNEY trial showed regardless use,2Herrington W.G. Staplin N. Wanner C. al.The...